The crystal structure of human a-thrombin in complex with LY178550, a nonpeptidyl, active site-directed inhibitor, has been solved to 2.07 8, resolution by the method of X-ray crystallography. The final model of the complex has a crystallographic R-value of 21.5% (Rfree = 23.1%) with 0.014 8, and 2.4" standard deviation from ideal bond lengths and angles, respectively. Well-defined electron density was observed for the inhibitor in the active site. The inhibitor binds to the active site in an L-shaped manner, mimicking the bound conformation of the tripeptide arginal series of thrombin inhibitors (Chirgadze NY et al., 1992 Keywords: crystallography; human a-thrombin; nonpeptidyl inhibitor; structure-based drug design Thromboembolic diseases remain a leading cause of mortality and morbidity in developed societies. Thrombin, a trypsin-like serine protease, is a key mediator in such disease states, primarily through fibrin formation and platelet aggregation (Machovich, 1984) . In response to the well-documented liabilities associated with the anticoagulant warfarin (Smith et al., 1988) , an industry-wide search has been initiated to discover safe and effective, orally active thrombin inhibitors that can be used in the chronic treatment of thrombotic disorders. Over the past few years, a number of very potent and selective inhibitors of thrombin have been identified based on the N*-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide (NAPAP), Argatroban (MD-805), the D-hAA-Pro-Arg [ M A = hydrophobic amino acids (Scarborough et al., 1995) ], and the methyl ester of N"-tosylated arginine (TAME) (Sherry et al., 1965) structural motifs. In general, however, the peptidyl nature of these classes of agents has been prohibitive of high oral bioavailability.
Thromboembolic diseases remain a leading cause of mortality and morbidity in developed societies. Thrombin, a trypsin-like serine protease, is a key mediator in such disease states, primarily through fibrin formation and platelet aggregation (Machovich, 1984) . In response to the well-documented liabilities associated with the anticoagulant warfarin (Smith et al., 1988) , an industry-wide search has been initiated to discover safe and effective, orally active thrombin inhibitors that can be used in the chronic treatment of thrombotic disorders. Over the past few years, a number of very potent and selective inhibitors of thrombin have been identified based on the N*-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide (NAPAP), Argatroban , the D-hAA-Pro-Arg [ M A = hydrophobic amino acids (Scarborough et al., 1995) ], and the methyl ester of N"-tosylated arginine (TAME) (Sherry et al., 1965) structural motifs. In general, however, the peptidyl nature of these classes of agents has been prohibitive of high oral bioavailability.
In an effort to identify nonpeptidyl inhibitors of thrombin that might have a more favorable pharmacokinetic profile than their peptide-related counterparts, we have prepared LY178550 (1- Figure 1 ) as an initial lead for future structure activity relationship (SAR) studies. Agent LY178550 was a result of docking studies of 5-amidino indole into the specificity pocket of the thrombin active site, and the realization that addition of a lipophilic side chain onto the indole nucleus would allow access to and interaction with the hydrophobic S3 pocket. Accordingly, LY 178550 consists of two primary components: (1) 5-amidinoindole, which has been employed previously as an arginine surrogate in the design of inhibitors of arginine endopeptidases (Geratz et al., 1979) and (2) a hydrophobic 4-benzylpiperidine tail.
Although analysis of Michaelis-Menton kinetics indicates that LY178550 is a competitive inhibitor of thrombin, we wanted to better characterize the active site binding orientation of this agent for future SAR studies. To this end, a co-crystal of thrombin, LY178550, and hirugen has been grown and the structure of the ternary complex solved by X-ray crystallography. The details of this study are reported below.
Results and discussion
The active site region of the human a-thrombin protein with the bound inhibitor (LY178550) is shown in Figure 2 . A schematic representation of the interaction pattern is given in Figure 3 . The inhibitor is completely defined by strong electron density, indica- (Chirgadze et al., 1992) . In the present case, however, the amidine is more favorably oriented for additional hydrogen bonding to the carbonyl oxygen of Gly 219 [266] . The indole N-H is oriented toward the catalytic Ser 195 [241] and forms a hydrogen bond with the y-oxygen. The amide carbonyl of ' The thrombin residue numbering used in this study is equivalent to that reported for chymotrypsinogen (Hartley et al ., 1971) . A sequential numbering scheme starting from the N-terminus of thrombin is shown in brackets. LY178550, which is directed away from the active site, appears to be positioned between and below the side chains of Glu 192 [238] and Trp 60D [86] . Together, these residues partially bury this ketone oxygen from the solvent. The side chain of residue Glu 192 [238] The affinity of LY178550 for human a-thrombin, as measured by it's association constant (Kass) is 2.00 2 0.5 X lo6 L/mole. The larger the K,, value, the stronger the interaction between enzyme and inhibitor. The apparent K,, value for LY178550 is approximately 1/100 the binding affinity of that found for the arginal tripeptide LY288570 (K,,, = 241 2 83 X lo6 L/mole) (Shuman et al., 1993) . The thrombin selectivity with respect to other serine proteases is indicated in Table 1 , given in ratios of protease KmS/ thrombin Kass. The relative selectivities of the two thrombin inhibitors are very similar, with each compound found to be almost as potent toward trypsin as toward thrombin. Compound LY 178550 inhibits human factor X, relatively more strongly than the arginal LY288570; otherwise, both compounds show good selectivity toward the other related enzymes. This difference in selectivity could be explained from a structural point of view. LY288570 has strong hydrophobic interaction with the S2 pocket, which is quite unique for thrombin. In contrast to LY178550, which does not capitalize that much on this particular binding site, the piperidine ring at the P2 position is just slightly touching the entrance of this deep, Thornton. 1994) using the default criteria. To interpret hydrophobic contacts, follow the spokes protruding from a ligand atom. toward a protein residue diagrammed as an arc. Spokes radiating back toward the atom indicate a potential interaction. mostly hydrophobic pocket, building up its affinity from other more conservative structural points of interaction.
In a general sense, inhibitor LY 178550 binds to the active site of thrombin in a similar orientation as the tripeptide arginal series of inhibitors, interacting at the SI, Sz, and S 3 subsites. Superposition of the active site conformation of LY178550 with that of the tripeptide arginal LY278550 is shown in Figure 4 . In LY 178550, the amidinoindole fragment serves as an arginine surrogate, forming a salt bridge with Asp 189 [235] ; the piperidine ring fills the site occupied by the pyrrolidine residue of LY288570; and the benzyl group resides in very nearly the same position as the aromatic portion of the tetrahydroisoquinoline ring at the S 3 site. In spite of the similarities, however, there are notable differences between the binding orientation of LY178550 and other active sitedirected inhibitors such as LY288570. The most significant is that LY178550 does not interact in any fashion with the active site sequence Ser 214-GIy 216 [262-2641. Most inhibitors studied previously, including LY288570, form a pair of hydrogen bonds with these residues in a manner typical of an anti-or a parallel P-strand (Malley et al., 1996) . The absence of this pair of hydrogen bonds could explain, in part, the modest thrombin inhibitory activity of LY178550 compared with the other classes of peptide-derived agents. In addition, the interaction of LY178550 with the active site induces the following small conformational changes compared to the structure of the native protein: the side chain of Trp 60D [86] turns out of the way, making the Sz pocket slightly wider; and the imidazole ring of His 57 [79] rotates toward the inhibitor molecule. Both of these factors, and others, likely influence the relative activity of LY178550 compared to other known thrombin inhibitors.
Recently, a report of a series of thrombin inhibitors based upon substituted 5-amidinoindoles has appeared (Iwanowicz et al., 1996) . Development of this series was guided by considering a computationally predicted binding mode for 5-amidinoindole in the S1 pocket from a previously determined, thrombin X-ray crystal structure complex (Tabernero et a!., 1995) . Comparing the 5-amidinoindole PI substructure, common to both LY 178550 and the reported series, we find general agreement in the overall binding mode. However, one notable difference exists in that the indole N-H (N12) is reported to form a hydrogen bond to the backbone carbonyl oxygen of Ser 214 [262] . This is in contrast to our experimental finding that this nitrogen forms a hydrogen bond to the y-oxygen of the catalytic serine, Ser 195 [241] . Other minor differences are apparent from the published stereo diagram of the computational binding mode of this common P, moiety. However, because this level of detail was not described previously, these differences will not be elaborated on. It is reasonable to attribute these differences to the well-known limitations of any empirical energy-based, computational docking technique (Ajay & Murko, 1995) . However, it is just as likely that the additional binding features present in LY178550 (Pz piperidine ring; P3 benzyl ring) induce the observed differences.
Using X-ray crystallography, we have characterized the binding orientation of LY178550 in the active site of human a-thrombin. This novel inhibitor binds in a fashion that is similar to, but in many ways different from other agents studied previously. The application of these results to the design of more potent thrombin 
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,Human proteases except for bovine trypsin. . An X-ray structure of the LY288570 complex has been determined previously in our laboratory at 2.2 A resolution.
inhibitors that possess promising pharmacokinetic profiles is ongoing.
Materials and methods
Human a-thrombin was obtained from Enzyme Research Laboratories, Inc. (South Bend, Indiana) as a pH 6.5 buffered solution in 50 mM sodium citrate, 0.2 M NaCl, and 0.1% PEG 8000, frozen at -80 "C. After thawing at 4 "C, the enzyme preparation was concentrated to 7.5 mg/mL with simultaneous buffer exchange by use of 10-mL stirred cell (Amicon), with a YMlO membrane, by washing five times with 25 mM NaP04, pH 7.5, 375 mM NaCI. Hirugen was purchased from Bachem Biosciences, Inc. (Philadelphia, Pennsylvania). Hirugen, which consists of residues 54-65 from the C-terminus of hirudin, binds noncovalently to the basic fibrinogen recognition exosite, as has been reported for related peptides (Skrzypczak-Janjun et al., 1991) . The presence of this peptide stabilizes a-thrombin by inhibiting autocatalytic cleavage of the Arg 77A-Asn 78 [109-1101 bond to yield p-thrombin.
The synthesis of amidinoindole LY 178550 was accomplished in a straightforward manner. Coupling of 5-cyanoindole-2-carboxylic acid (Lindwall & Mantell, 1953 ) with 4-benzylpiperidine afforded the nitrile amide derivative of LY178550. Conversion to the target amidine was accomplished using conditions of Pinner (Ashley et al., 1942) . The chemical formula of LY178550 is shown in Figure 1 . The binding affinity of the inhibitor to human thrombin (and other serine proteases) was determined as apparent association constant (Kass) derived from inhibition kinetics, as described previously (Schacht et al., 1995; Smith et al., 1996) . Enzyme inhibition kinetics were performed in 96-well polystyrene plates and rates of reaction were determined from hydrolysis rates of appropriate p-nitroanilide substrates at 405 nm using a Thermomax plate reader from Molecular Devices (San Francisco, California). The same protocol was followed for all enzymes studied: 50 pL buffer in each well, followed by 25 pL of inhibitor solution, and 25 pL enzyme; within 2 min, 150 pL chromogenic substrate was added to start the enzymatic reactions. The rates of benzoyl-Phe-Val-ArgpNA hydrolysis reactions provide a linear relationship with human thrombin such that free thrombin can be quantitated in reaction mixtures. Data were analyzed directly as rates by the Softmax program to produce [free enzyme] calculations for tight-binding Kass determinations (Schacht et al., 1995; Smith et al., 1996) . For apparent Kass determinations, 5.9 nM human thrombin and 1.4 nM bovine trypsin were used to hydrolyze 0.2 mM Bz-Phe-Val-ArgpNA; 3.4 nM human plasmin with 0.5 mM HD-Val-Leu-Lys-pNA; 1.2 nM human nt-PA with 0.81 mM HD-Ile-Pro-Arg-pNA; 0.37 I N urokinase with 0.30 mM pyro-gfsGlu-Gly-Arg-pNA; 1.34 nM human factor X, with 0.18 mM BzIly-Glu-Gly-Arg-pNA; and 2.9 nM aPC with 0.175 mM Glu-Gly-Arg-pNA.
Crystals of the apo-enzyme in complex with exosite-bound hirugen, that were suitable for X-ray data collection, were grown from a solution of 6 mg/mL human a-thrombin with three molar equivalents hirugen equilibrated against 150 mM sodium citrate, pH 5.6, 30% PEG 4000, and 200 mM ammonium acetate, using the vapor diffusion technique at 4 "C. Single crystals appeared during a 2-week period. They belonged to the monoclinic space group C2 with unit cell parameters of a = 71.5 8, b = 72.0 8, c = 73.0 A, and p = 101.03". The crystals contain one molecule per asymmetric unit.
The enzyme/inhibitor complex was obtained by soaking the enzyme crystal in a 5 mM LY178550 solution for one day. An X-ray diffraction data set was collected using CuK, irradiation from a conventional Rigaku RU200 X-ray source (Shibata, 1990) with a copper rotating-anode generator, operating at 50 mV and 90 mA with a fine ,focus of 0.3 X 3.0 m m 2 . A Pt and Ni mirrors focusing system from Molecular Structure Corporation (Houston, Texas) was used. An R-AXIS IIc with a Fuji imaging plate was used as the detector (Shibata, 1990) . Data set was collected from a single crystal at room temperature. The diffraction data were reduced using the DENZO program (Minor, 1993) and the intensity scaled with the SCALEPACK software (Otwinowski, 1993 Crystallographic refinement of positional and individual temperature parameters was performed using the program X-PLOR (Briinger, 1992) and the force field parameter dictionary PARHCS-DX.PR0 of Engh and Huber (1991) . A previously reported thrombin structure was used as an initial model (Chirgadze et al., 1992;  resolution 2.2 A, R-value = 15.6%). The inhibitor molecule was situated into the active site based on the electron density Fourier maps with calculated (2F0 -F,, ac) and (F, -Fc, ac) coefficients after a few cycles of the refinement in which the inhibitor was not included in the refinement procedure. Visual inspection and man- ual correction of the model between rounds of refinement were performed using the QUANTA interactive graphics program (Molecular Simulations Inc., San Diego, California). A final crystallographic R-value of 21.5% for 19,947 reflections with F > 2u in the resolution range 6.0-2.07 8, was obtained. An Rfree (Briinger, 1992 ) of 23.1% was calculated using a random selection of approximately 10% of the experimental data. The Rh4S deviation from ideal bond lengths and bond angles were 0.014 A and 2.4", respectively. For the Ramachandran plot (not shown), no residues appeared outside of the commonly accepted regions. A mean positional error of approximately 0.3 8, was estimated from a Luzzati plot (Luzzati, 1952; data not shown) .
Crystallographic data and refinement statistics are shown in Tables 2 and 3. 
